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The overuse of antibiotics is a large problem in healthcare today, accelerating the 
development of microbial resistance to antibiotics. Antibiotic stewardship campaigns 
have been implemented to help clinicians curb their use. Procalcitonin is a serum peptide 
and marker of inflammation secreted in response to microbial toxins. For this reason it is 
more specific to bacterial infections than other markers of general inflammation , like C-
reactive protein. The population of patients with sepsis in the Intensive Care Unit is one 
in which extended durations of antibiotics are used. The FDA has approved use of 
procalcitonin to guide de-escalation of antibiotic therapy in critically ill patients with 
sepsis to avoid both antibiotic overuse and antibiotic related side effects. Review of 
current literature shows that procalcitonin is efficacious in reducing duration of antibiotic 
therapy in patients with sepsis in the ICU setting. This result, however, is not being 
observed in clinical practice. This discrepancy is due to the inappropriate use of 
procalcitonin that does not align with use outlined in randomized control trials. We 
propose a study to determine how procalcitonin is being used in clinical practice in four 
Boston area hospital Intensive Care Units. Through chart review, we will identify patients 
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in the Intensive Care Unit with sepsis from 2013-2018 recording patient demographic 
information and patient characteristics. We will determine whether they had PCT 
measured during their stay, and if they did, whether or not discontinuation of antibiotics 
was in accordance with FDA’s proposed algorithm. We will aim to compare whether 
discontinuing antibiotic therapy in accordance with the FDA’s procalcitonin de-
escalation algorithm is associated with reduced duration of antibiotic therapy or incidence 
of Clostridium Difficile infection. In conducting this study, we hope to identify patterns 
of procalcitonin use in clinical practice and provide further evidence that using the 
algorithm to guide therapy can serve as an effective tool in reducing exposure to 
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Antibiotics are one of the greatest tools developed in medicine to treat life threatening 
infections. However, according to the CDC, between 20-50% of antibiotics prescribed in 
the U.S. are deemed either unnecessary or inappropriate.1 As a result, the overuse has 
accelerated the development of resistant strains2, making resistance to antibiotics a major 
public health concern in the United States and across the globe.2,3  Unnecessary antibiotic 
treatment is associated with the risk of possible side effects including allergic reaction, 
colitis and increased risk of infection with multidrug resistant organisms especially in 
those on long standing antibiotic therapy.4 One solution proposed to slow the rate of 
development of resistance is through antibiotic stewardship. Overall, antibiotic 
stewardship can be described as a variety of interventions on multiple levels that aim to 
decrease inappropriate use of antibiotics by encouraging use of optimal antibiotic 
regimen which includes appropriate agent, dosing and duration of therapy.5  Improved 
patient outcomes and reduction of adverse events associated with increased antibiotic use 
like Clostridium Difficile Infection (CDI), are some of the benefits of practicing antibiotic 
stewardship.5Recommendations from the IDSA for antibiotic stewardship are 
multifaceted. In particular, one way of practicing antibiotic stewardship recommended by 
the IDSA with mild-moderate evidence is by using Procalcitonin (PCT) for antibiotic de-
escalation.5 
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Procalcitonin (PCT) is a precursor of calcitonin, a hormone produced primarily by 
C-cells in the thyroid. Under normal conditions PCT concentrations are negligible but 
rise during bacterial infection as PCT is upregulated by microbial toxins.6,7 Furthermore, 
PCT levels are thought to correlate with the severity of the infection with more extensive 
infections having higher peak PCT.6,8,9 In 2017, the FDA officially released a statement 
recommending the use of  PCT10 in the two following ways: to guide both initiation and 
discontinuation of antibiotics in patients with lower respiratory tract infections; and to 
guide only the discontinuation of antibiotics in patients with sepsis.10,11 12 
Current antibiotic standards of care for patients with sepsis recommend starting a 
course of an empiric, broad spectrum antibiotic tailored to the suspected source of 
infection.12 The duration is individualized, and often patient and provider dependent. The 
typical course is 7-10 days, while some can be as long as 21, averaging at 10-14 days per 
course. 4,13 Misuse and overuse of antibiotics have the potential to lead to more adverse 
effects. 14 Patients with sepsis who are not treated with adequate antimicrobial therapy on 
admission to the ICU have greater  mortality and morbidity15 and furthermore, de-
escalating the empirical antibiotics is associated with decreased mortality in patients with 
severe sepsis and septic shock.14  The primary goal of PCT guided therapy is to decrease 
unnecessary use of antibiotics and, therefore, decrease the opportunity for development 
of resistance and antibiotic related complications associated with long term use.16 
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Statement of The Problem 
Many of the randomized control trials performed have shown the efficacy of using PCT 
to guide antibiotic therapy.4,12,17–19 These studies have shown a 2 to 3 day reduction in the 
mean length of antibiotic therapy despite an adherence rate of only about 50% to the PCT 
protocol.20  Most of these studies were done in Europe and while the use of PCT has 
become more prevalent in the United States, the benefit of it has not translated into 
clinical practice.9,20  The Procalcitonin Antibiotic Consensus Trial was the first study 
investigating the usefulness of procalcitonin levels in guiding antibiotic therapy in the 
United States and they found that the use of PCT to guide treatment did not result in less 
antibiotics used when compared to the standard of care.9  A similar study investigating 
practice patterns in the United States within ICU settings demonstrated that clinicians are 
not using the PCT test the way in which it has been shown to be efficacious in  
randomized control trials20. Given the inconsistency of PCT use, more effort should be 
made in implementing PCT into practice in order to have better results in the clinical 
setting.  
The FDA now recommends the use of their algorithm to discontinue antibiotics in 
patients with sepsis. However, it is unclear how PCT use has evolved in clinical practice 
and whether or not following recommended algorithms for its use is efficacious in 
decreasing duration of antibiotic therapy and reducing adverse events associated with 
antibiotic overuse like CDI.  




The discontinuation of antibiotic therapy in critically ill patients with sepsis that was 
executed in accordance with current FDA recommendations will result in an observed 
reduction in duration of antibiotic therapy and reduced incidence of CDI when compared 
to the control. Furthermore, in patients who had PCT measured but whose antibiotic 
therapy was not executed in accordance with the FDA recommendations will have an 
observed increase in duration of antibiotic therapy and increased incidence of CDI 
compared to those whose antibiotic therapy was tailored in accordance with the 
algorithm.     
Objectives and specific aims 
The primary objective of this study will be to observe the patterns of PCT use in septic 
patients in the ICU, including what types of patients are tested for PCT concentrations, 
and its effect on length of antibiotic course. In doing so, we will observe the efficacy of 
the FDA’s procalcitonin algorithm for guiding antibiotic de-escalation in shortening 
duration of antibiotic therapy and its effect on the incidence of CDI. Specifically, this 
study aims to:   
• Compare the mean length of antibiotic usage with different patterns of PCT 
usage.   
• Compare the incidence of CDI with different patterns of PCT usage.     
• Identify how group characteristics differ with patterns of PCT usage. 
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REVIEW OF THE LITERATURE 
Overview 
Antibiotic Resistance 
According to data collected by the Center for Disease Control, at least 2 million people in 
the United States get infections with antibiotic-resistant strains of bacteria with at least 
23,000 people dying as a result of these infections.21 Resistance to antibiotics develops 
over time when bacteria, through genetic changes, evolve mechanisms to overcome the 
medication designed to kill them.2,3 While this process occurs naturally, overuse and 
misuse of these lifesaving drugs, speeds up this phenomenon.2 The first incidence of the 
development of antimicrobial resistance was in 1940 to the drug penicillin. Since 2000, 
only 3 new antibiotics have been developed and in that time alone, at least 10 new 
resistant strains have emerged21. New mechanisms of resistance are developing and 
reaching all continents,2 problematic as antimicrobial resistance can lead to prolonged 
illness, increased cost of health care and even death.2 It is estimated that people infected 
with Methicillin-resistant Staphylococcus aureus( MRSA) are 64% more likely to die 
than those infected with a nonresistant strain2.  While these strains are resistant to the first 
line treatment second line agents have fortunately been developed to treat MRSA 
infections. More ominous are the resistant strains emerging to our last line of defense in 
treating some infections. For example, carbapenems are the last line of therapy in treating 
Klebsiella pneumoniae infections and, according to the World Health Organization, today 
carbapenem resistant K. pneumoniae can be found on all continents of the world.2 
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Because of these trends in antibiotic resistance, the WHO has called for innovation and 
investment in research to develop vaccines against and diagnostic tools for resistant 
strains.2 Additionally, the CDC has outlined core recommendations to integrate effective 
antibiotic stewardship programs into practice to help providers responsibly prescribe 
antibiotics improving patient quality of care and reducing hospital rates of resistance.1,22 
Sepsis 
As defined by the Third International Consensus Definitions for Sepsis and Septic Shock 
(Sepsis-3) in 2016, sepsis is a syndrome of life-threatening organ dysfunction caused by 
dysregulated host response to infection (presumed or confirmed).23  This is a new 
definition that deviates from the previously ones outlined in Sepsis-1 and Sepsis-2 which 
defined sepsis as a systemic inflammatory response syndrome due to infection..24 Sepsis 
can occur when an infection is not identified and goes untreated.25  It is a result of 
hypersecretion of pro-inflammatory cytokines, including TNFa, IL-1b and IL-6 which  
triggers an immune response and can cause cell death.8 When regulated in a normal 
immune response these cytokines are helpful in fighting infection, however, when they 
are hyper secreted in sepsis it can progress to organ failure and death.8,26  The World 
Health Organization estimates that sepsis affects 30 million patients each year  worldwide 
and potentially causes 6 million deaths.27 In America alone, the CDC reports that at least 
1.7 million adults develop sepsis annually and, furthermore, 1 out of 3 patients who die in 
a hospital has sepsis.28  Individuals who are at increased risk of developing sepsis 
include: those less than 1 year old, those more than 65 years old and those with medical 
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conditions such as diabetes, chronic lung disease and chronic kidney disease. Patients 
who are immunocompromised, those with indwelling devices and those with lower 
socioeconomic status and access to healthcare are also at increased risk.25,29  While sepsis 
is due to an infection, cultures in patients who are presumed to have sepsis are only 
positive 50% of the time due to technical errors as well as timing of specimen collection.8 
             Over the past two decades, clinicians have been striving to determine better ways 
of early detection and management of sepsis.23,26,30 The third international conference, 
Sepsis 3,  outlined two standards for identifying organ dysfunction.24 One is a sequential 
organ failure assessment score (SOFA) which assesses organ function of 6 organ systems 
on a scale of 0-4 using various lab values that are indicative of function.24 Using SOFA, 
sepsis is defined as an increased score of 2 pts or more. An alternative method to screen 
for susceptibility of developing sepsis is the qSOFA score or quick SOFA, in which 
clinicians can screen patients for those at risk for developing sepsis.23,24 The qSOFA is 
beneficial as it does not require the extensive laboratory results that the SOFA does and 
because of this can be repeated often. Patients are at risk for sepsis if they meet 2 out of 
the 3 following criteria: altered mental status; respiratory rate greater than 22 breaths per 
minute ; or a systolic blood pressure less than100 mmHg.23,24 The objective of  these new 
definitions is to guide earlier recognition of patients at risk for sepsis and to track 
progress/course of septic patients to effectively treat them.23 
 




Procalcitonin (PCT) is a 116 amino acid precursor of the hormone calcitonin and is 
primarily found in the C cells of the thyroid as well as in the pulmonary endocrine cells, 
although all tissues in the body are capable of producing it. In typical physiologic settings 
it is secreted in response to hypercalcemia.6,8,31 Under normal physiologic conditions 
PCT concentrations in serum are negligible.6,31 Procalcitonin levels are modulated both 
by bacterial toxins such as lipopolysaccharides(LPS) and lipotechoic acid (LTA) as well 
as sepsis related cytokines.31  Lipopolysaccharides are endotoxins found in the cell wall 
of many gram negative bacteria32 and Lipotechoic acid is found in Gram-positive 
bacteria.8 The initial trigger for release of serum PCT is primarily circulating bacterial 
toxins such as LPS or LTA from infection.8 Following this rise in serum procalcitionin 
concentration there is a subsequent release of other cytokines thought to be TNF a, IL-1 
and IL-6 and other mediators yet to be  identified.8   
             Given the biological response of PCT to bacterial endotoxins, it is logical that 
PCT has shown to be useful specifically in treating bacterial infections when compared to 
generalized markers of inflammation like C-reactive protein (CRP).  Inflammatory 
markers, like CRP, are less specific than PCT as they can be elevated during processes 
such as viral infections, or rheumatologic conditions. 4,9,31,33 The elevation in PCT has 
been found to correlate with the severity of bacterial infection. 8,9 After cells have been 
stimulated, secretion of PCT begins within 4 hours and peaks at 8 hours, only clearing  
once the stimulus is controlled.6,31  In contrast, CRP rises after 12-24 hrs and peaks at 48 
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hours or more, decreasing its accuracy in monitoring  inflammatory insult.4,6 Lastly, PCT 
is stable in serum samples and the results are available within 2-4 hours6,31 which make it 
potentially useful in daily practice. 
Existing research 
Layios and coworkers in their 2012 study evaluated the usefulness of PCT concentrations 
in reducing antibiotic consumption in patients with potential infections in the ICU. This 
was a single center, prospective randomized control trial, specifically investigating 
whether procalcitonin was useful in determining when to initiate antibiotic treatment. The 
study included 509 subjects who were randomized to control (n=251) or to the PCT 
guided group (n=258). Procalcitonin levels were drawn when patients were suspected of 
developing infection and the results were given to treating physicians in the PCT group. 
If PCT was <0.25ng/mL initiation of antibiotic therapy was strongly discouraged and if 
PCT was >1ng/mL, they were strongly encouraged. There was no difference in antibiotic 
consumption found between the two groups. They did find, however, that 33.8% of cases 
in which no infection had been confirmed, the PCT value was falsely positive (>1ng/mL) 
and in 14.9% of the cases with confirmed infection the PCT was falsely negative 
(<0.25ng/mL).34 This indicates that the specificity of procalcitonin for diagnosing 
bacterial infection is low. Areas of weakness of this study include low adherence to the 
PCT guidelines initiating antibiotics. In fact, antibiotic therapy was only initiated in 
46.3% of patients whose PCT level aligned with the suggestions. This study demonstrates 
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that there may be little utility in using PCT to initiate antibiotic treatment to decrease 
antibiotic consumption in the ICU.  
Jensen et al also tried to determine whether PCT was a useful metric for the need 
to escalate antibiotic therapy and improve 28 day mortality, when compared to the 
standard of care antibiotic therapy in Denmark.35  Appropriate antibiotic therapy in sepsis 
is known to reduce mortality and morbidity.15 The study, much larger than Layios et. al., 
included 1200 patients who were randomized to either a PCT intervention group or 
control group. In the study, if a PCT concentration was found to be greater than or equal 
to 1.0 ng/mL, treating physicians were advised to escalate antibiotic therapy. Escalating 
therapy was to include a combination of both broadening the spectrum of antimicrobial 
coverage according a provided site specific algorithm and increasing the diagnostic effort 
in order to identify the source of the infection. There was adequate adherence to this 
protocol with 82.1% of patients receiving antimicrobials according to the algorithm. The 
use of antimicrobial therapy measured in defined daily doses administered within 1-28 
days was significantly increased in the procalcitonin group specifically for the use of the 
following; Piperacillin/tazobactam (p<0.001), Cefuroxime (p<0.001) and Ciprofloxacin 
(p<0.001). Importantly, the time to appropriate treatment administered was not different 
between groups, with the exception of those who had bacteremia. There was no statistical 
difference between groups in 28-day mortality. Among the secondary outcomes that were 
notable, the PCT guided group had a significantly longer length of stay when compared 
with the control group (p=0.004). Given the results of their study Jensen and colleagues 
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concluded that using PCT as a guide to initiate treatment did not improve survival and led 
to increased use of broad-spectrum antibiotics. They attributed this increased use to both 
longer length of stay in ICU and to the protocol’s requirements for escalation in antibiotic 
therapy. This study had a large sample size and, thus, greater statistical power, as well as 
much higher adherence rates. However, the generalizability of this study is questionable 
as all 9 centers studies were in Demark, a place in which the standard of care 
antimicrobial treatment is much more conservative than other places in the world. Overall 
this study provided more evidence that PCT was not efficacious in initiating antibiotic 
therapy in critically ill patients.  
Despite data suggesting that PCT is not useful for the diagnosis of sepsis and the 
initiation of antibiotic treatment, there is evidence suggesting its efficacy when used to 
guide antibiotic discontinuation among critically ill patients with sepsis. Nobre et.al 
conducted the first randomized control trial to determine whether the use of PCT levels in 
septic patients could shorten the duration of antibiotic treatment in 200812 . In their study 
they created a protocol that used serial PCT measurements during the patient’s admission 
to the ICU. Patients in the control group received standard of care, empiric therapy. For 
patients in the intervention group, the use of antibiotics was stopped based on a defined 
set of stopping rules. Patients whose baseline PCT level was greater or equal to 1 ng/mL 
at baseline were reevaluated at day 5. For these patients, on day 5 antibiotics were 
discouraged when PCT dropped more than 90% from the baseline peak level or an 
absolute value < 0.25 ng/mL was reached.  Patients with a baseline PCT less than 1 
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ng/mL were reevaluated at Day 3 and discontinuation was encouraged at this time if PCT 
was <0.1ng/mL.  However, these rules were subject to being overruled by clinical 
judgement of the patient’s condition. The primary outcome of this study was systemic 
antibiotic exposure. This was measured using the three following variables: duration of 
antibiotic treatment(days of therapy given for the initial episode of infection), antibiotic 
exposure days(a period of continuous administration of a single antibiotic for more than 
24 hours per 1,000 inpatient days) and days alive without antibiotics(period of at least 24 
hours without antibiotic administration)12. In the intention to treat analysis they found the 
median duration of antibiotics  to be shorter in the PCT guided group than the control 
group by 3.5 days, a difference found to not be statistically significant (p = 0.15). 
Additionally, both the difference in total antibiotic exposure days as well as days alive 
without antibiotics were not statistically significant (p=0.07 and p=0.28, respectively). 
Due to dropout, only 68 patients(n=37 in control group, n=31 in PCT ) reached a time 
when a decision could be made about stopping antibiotics. Upon analysis of this group, 
the median antibiotic duration for the first episode of infection was lower among those in 
the PCT group compared to controls by 4 days, a difference which was found to be 
statistically signficant(p=0.003). Adittionally, patients whose antibiotic therapy was 
guided using PCT had significantly fewer total antibiotic exposure days (p=0.002). 
Lastly, the mean number of days alive without antibiotics was found to be statistically 
significantly greater in patients with the PCT group compared with those in the control 
group (p=0.04). While Nobre et. al found that individuals assigned to the PCT group had 
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reduced antibiotic use in the absence of harm to the patients, the study has a few notable 
limitations. First, it was a single center study with a relatively small sample, limiting its 
generalizability. Second, as this is a tool to be used in combination with clinical 
discretion, researchers were allowed to overrule the PCT protocol if they felt the patient’s 
clinical condition required continued antibiotic use. This leads to a potential 
conservative-bias that numerous studies of PCT- guided treatment have been faced with. 
Patients who clinically might not look as sick are more likely to have their antibiotics 
discontinued, while those whose clinical picture may appear more critical will be 
maintained on antibiotics regardless of downtrending PCT. Unfortunately, as this was 
allowed in the stopping rules, it is difficult to correct for this conservative-bias. However, 
this bias may actually lead to an underestimation of the true efficacy of PCT guided 
discontinuation. Additionally, it is important to note that this study -- one of the first 
RCTs investigating PCT-guided treatment in the ICU setting -- was funded by BRAHMS 
AG, the maker of the PCT assay used in this study. They authors note no conflict of 
interest though.   
Schroeder and colleagues published a similar study to Nobre et.al in 2009 
investigating use of PCT-guided antibiotic treatment to reduce duration of antibiotics in 
patients with severe sepsis among patients in a surgical ICU. They conducted a 
prospective, randomized study to determine the usefulness of daily serum PCT 
measurements in guiding the length of antibiotic treatment in surgical ICU patients with 
severe sepsis. Patients were randomly assigned to PCT-guided antibiotic treatment or a 
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control group which received standard of care antibiotic therapy according to empiric 
rules. In the PCT- guided treatment group, antibiotic therapy was to be discontinued, if 
the patient was clinically improved and PCT values either had decreased to 1ng/ml or less 
or had dropped to 25-35% of the initial PCT concentration over  a three day period.4 
Similarly to Nobre et. al, the discontinuation of antibiotic therapy was subject to overrule 
by the physician’s clinical judgement. Schroeder et. al found the length of antibiotic 
treatment to be 6.6 +/- 1.1 days in the PCT- guided group and 8.7+/- 0.7 days in the 
control group, a statistically significant difference (p<0.001).  They ultimately concluded 
that in concert with clinical judgement, PCT values have a role in contributing to less 
extensive antibiotic use. The limitations of this study are several and include that it is a 
single ICU study with small sample size, limiting its generalizability. Secondly, as with 
previous studies, there was a conservative bias in that physicians could over rule the PCT 
protocol and continue antibiotics using clinical judgement which could lead to an 
underestimate of the true efficacy of PCT protocol.  Furthermore, similarly to Nobre et. al 
2008, authors of this study were affiliated with BRAHMS AG the maker of the PCT 
assay.  
Hochreiter et. al also investigated the use of PCT in guiding antibiotic therapy 
duration in surgical ICU patients but used a larger sample size than Schroeder et. al with 
57 patients in the PCT- guided therapy group and 53 patients in the control group18. 
Similarly, patients in the surgical ICU with confirmed or high-grade suspected infections, 
were randomized into a PCT guided group and a control group. The author followed the 
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same PCT algorithm as Schroeder et.al. to guide discontinuation of antibiotic therapy in 
the PCT group. The control group was treated following the standard 8-day antibiotic 
regimen. Hochreiter et. al found that  antibiotic therapy in the PCT guided group was 5.9 
SD +/- 1.7 days, significantly shorter than in the control group with 7.9  SD +/- 0.5 days 
(P<0.0001). Furthermore, there were no observed adverse effects or negative clinical 
outcomes, providing further evidence that the use of PCT-guided antibiotic 
discontinuation is both safe and efficacious. As with prior studies, this was a single center 
study which limits the generalizability and physicians were allowed to overrule PCT 
algorithm using clinical judgement which introduces the conservative bias observed in 
prior studies. It is important to note that one of the authors has received payments for 
speaking engagements from BRAHMS, the makers of the PCT assay used in the study.  
Many of the previously mentioned studies provided evidence as to the usefulness 
of PCT to guide antibiotic therapy among septic patients in the ICU. However, they were 
all single center studies with relatively small sample sizes. Lila Bouadma and Colleagues 
conducted a multicenter, prospective, open-label trial (PRORATA trial) to further bolster 
the evidence that PCT could be a useful tool to not only decrease antibiotic use in the 
ICU but also decrease ICU related costs and, importantly, decrease antibiotic resistance 
from antibiotic overuse. 17 In this study, critically ill patients with suspected bacterial 
infections at admission to the ICU were randomly assigned to either control or PCT 
group in a 1:1 ratio. There were 307 patients in the PCT group and 314 in the control 
group included in the analysis. The control group received a reminder which outlined the 
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recommendations for duration of antibiotic therapy in frequent infections to guide their 
care, however they were able to freely determine the therapy17. In contrast to prior 
studies, PCT levels were used to determine both whether to start antibiotic treatment and 
when to stop antibiotic use in the PCT-guided therapy arm. The PCT-guided algorithm 
strongly discouraged antibiotic initiation if PCT concentration was <0.25ng/mL, and 
strongly encouraged it when PCT concentrations were >/= to 1 ng/mL. The PCT-guided 
stopping rules were more conservative than those used in prior studies. Investigators were 
encouraged to stop treatment with antibiotics when PCT levels had dropped by more than 
80% of the peak PCT concentration or when the absolute PCT concentration was less 
than 0.5 ng/mL. Additionally, as with prior studies using PCT guided antibiotic therapy, 
the final decision to begin, continue or stop antibiotic therapy in the PCT group was up to 
the clinical judgement of the physician. The trial was designed to determine whether 
PCT-guided antibiotic therapy was superior to standard of care in terms of antibiotic use 
and non-inferior in terms of mortality. The primary outcomes were death at days 28 and 
60 and number of days without antibiotics 28 days after inclusion in non-inferiority 
analysis with a margin of 10%. Secondary outcomes included duration of antibiotic 
treatment and days of exposure to each antibiotic per 1000 inpatient days.17 The authors 
reported that mortality in the PCT guided group seemed to be non-inferior to those in the 
control group at day 28 (21.2% in the PCT group vs 20% in the controls; absolute 
difference 0.8%, 90% CI - 4.6 - 6.2) and at day 60 (30% in the PCT- guided group vs 
26.1% in the controls; absolute difference = 3.8%, 90% CI - 2.1 to 9.7). In the 28 day 
    
17 
 
period following inclusion, patients in the PCT guided group had a 23% reduction in 
antibiotic exposure compared to those in the control group. Lastly the patients in the PCT 
group had significantly more days without antibiotics,14.3 days (SD 9.1 days), when 
compared to the control group who had 11.6 days (SD 8.2) without antibiotics (absolute 
difference; 2.7 days, 95% CI: 1.4 to 4.1). It is important to note that physician discretion 
as allowed by the PCT-protocol resulted in 219 episodes where the PCT guidance 
protocol was not followed. The following were the reasons for nonadherence: physicians 
judged that infection could not be ruled out despite PCT of less than 0.5ng/mL (n=65); 
the initiation of antibiotics was postponed in patients who had a PCT of greater than 
0.5ng/mL when physicians thought PCT elevation was explained by a cause other than 
infection (n=4); antibiotics were stopped as physicians deemed infection was clinically 
cured despite PCT levels above 0.5ug/L (n=39); and, lastly, antibiotics were continued 
against protocol in 111 patients. Thirty-two of the 111 were discharged and lost to follow 
up while 79 were deemed clinically unstable despite PCT level below 0.5ug/L. In total, 
the algorithm was not adhered to in 162 patients, or 53% of the PCT-guided group. A 
similar adherence rate was found amongst the control group with only 45% adherence to 
standard of care recommendations. As this study was a multicenter RCT, it has greater 
generalizability than the single center trials.  Given the large rates of nonadherence 
however, it is difficult to assess the true accuracy of the estimates and warrants further 
investigation to validate both the efficacy and safety of PCT guided antibiotic therapy. 
This trial, as with all previous studies published in favor of PCT guided antibiotic therapy 
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in the ICU, was partially funded by the BRAHMS AG, the makers of the PCT assay used 
in this study.  
Previous research studying the efficacy of PCT algorithms for discontinuing 
antibiotics have had poor adherence to PCT protocol. Deliberato and colleagues, 
however, were able to achieve better adherence while demonstrating its safety and 
efficacy. They assessed whether PCT guided antibiotic treatment could reduce the 
duration of antibiotics in patients in the ICU with proven sepsis, severe sepsis or septic 
shock. For the per-protocol analysis they had a total of 51 patients (n= 20 in the PCT 
group n=31 in the control).  Patients in the control group received standard of care 
antibiotic therapy and, for those in the PCT group, antibiotic treatment duration was 
guided by a specified PCT protocol. Their primary outcome was duration of antibiotic 
therapy and secondary outcomes included in-hospital mortality, ICU mortality, primary 
infection relapse rate, CRP level analysis and cost. The algorithm suggested 
discontinuation of antibiotics when PCT dropped more than 90% from the peak level or 
an absolute value of <0.5 ng/mL was achieved36 . Treating physicians were encouraged to 
follow this protocol but they could overrule the protocol using clinical judgement. They 
found that the median duration of antibiotic therapy in the intention to treat analysis was 
10 days(PCT group) vs. 11 days (control group) (P=0.44) and in the per protocol 
analysis, median duration of antibiotic therapy was 9 days(PCT group) vs 13 days 
(control group) (p= 0.008). Researchers found no significant difference in in-hospital 
mortality, ICU mortality, or primary infection relapse rate. In none of the patients 
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evaluated did the CRP levels at the end of antibiotic treatment return to baseline when 
PCT levels of all patients had returned to normal. In the control group the total cost per 
patient was $1365.56 while the total cost per patient in the PCT group was $977.40, a 
savings of $388.25 per patient using the PCT algorithm despite the added cost of PCT 
assays. Of note, not all attending physicians agreed to participate in this study, so those 
who did choose to participate were perhaps motivated to adhere to the protocol, resulting 
in the high adherence. The authors concluded that PCT use is both safe and efficacious in 
shortening duration of antibiotics in critically ill patients with proven sepsis. This study’s 
primary limitation was that it was a single center trial with a small number of patients in 
analysis. With this study, Deliberato and coworkers demonstrated that in patients with a 
proven bacterial infection, PCT is useful as a means of guiding discontinuation of 
antibiotics to reduce patient exposure to antibiotics as well as decrease cost per patient.  
Bloos and colleagues published a large multicenter, randomized control trial in 
which they investigated the efficacy of antibiotic therapy guided by procalcitonin37. A 
total of 1089 patients were randomized for the intention to treat analysis 552 under PCT 
guidance and 537 in the control group. The PCT guided treatment group followed a 
specific algorithm unlike any of the prior algorithms that had been studied.  In their study 
patients in the PCT group had PCT measured on day 0,1,4,7,10 and 14. PCT on day 0 or 
1 was the baseline. On Day 4 if the PCT had dropped by at least 50% of baseline, it was 
recommended to continue current therapy. In their protocol, escalation in antibiotic 
therapy and diagnostic measures were encouraged if PCT was not reduced by 50% on 
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day 4, methodology for which PCT has not demonstrated efficacy in previous trials34,35. 
On other days, discontinuing antibiotics was recommended if PCT was < 1.0 ng/mL or if 
PCT had dropped by at least 50% of baseline.  The study’s primary outcome was death 
from any cause by day 28 for which they found no difference among the groups (25.6% 
in the PCT group and 28.6% in the control group; p=0.34), suggesting that PCT guided 
de-escalation algorithms are not associated with an increased mortality. Antibiotic 
exposure per 1000 ICU days was a secondary outcome measured for which there was a 
significant reduction (4.5%, p=0.02) in exposure in the PCT group. Similar to previous 
studies, the authors struggled with physician adherence and reported that physicians 
overruled the PCT protocol which recommended stopping antibiotics in 50.4% of cases 
due to presence of fever, microbiologic findings and white blood cell count37. This study 
is strong in that it was multicenter with an adequate sample size.  Despite the poor 
adherence, the study demonstrates the safety of using PCT for discontinuation of 
antibiotic therapy and suggests that using the PCT algorithm could reduce antibiotic 
exposure, although the authors did not investigate duration of antibiotic therapy or related 
adverse effects of antibiotics like CDI.  
In 2014 Shehabi and colleagues published a multicenter, prospective, single-blind, 
randomized control trial investigating whether a PCT guided algorithm with a low PCT 
cut-off  had an effect on antibiotic consumption38. Their study included 394 patients who 
were randomized to either standard of care or PCT guided cessation of antibiotics. The 
treating physicians were to stop antibiotics if any PCT measurement was <0.10 ng/mL or 
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if PCT level declined more than 90% from baseline38. This was a much more 
conservative cut off as many prior studies showed efficacy using a PCT cutoff of <0.5 
ng/mL. Physicians were to use this protocol in conjunction with the clinical picture and 
were allowed to overrule the algorithm if they felt it was necessary. Overall, the median 
number of antibiotic treatment days were 9 (PCT guided) and 11 (control), which was 
found to be a non-significant difference (P=0.58). One of the strengths of this study, in 
contrast to many before it, was the notably high adherence to the protocol which the 
researchers attributed to the low PCT level designated as the cut-off point. In the study 
limitations the authors discuss that their study was only powered to detect a 25% 
reduction in antibiotic duration (which translates into 3.75 days), the reason a 2-day 
reduction was statistically nonsignificant. Additionally, they note that the standard of care 
antibiotic therapy in Australia included antibiotic stewardship practice already, unlike the 
standard of care in previous randomized trials. This may have resulted in a more 
conservative use of antibiotics amongst controls and ultimately translating to less of a 
difference observed between control and PCT group. This study did not demonstrate a 
statistically significant reduction in antibiotic usage using the designated protocol using a 
conservative PCT cutoff value of <0.1ng/mL however, and authors endorse the need for 
further research to define a more universal algorithm – one that will safely and 
consistently result in reduced antibiotic duration and subsequently reduce ICU costs and 
development of antibiotic resistance.  
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De Jong and colleagues published one of the largest studies to date on 
procalcitonin guidance of antibiotic therapy in critically ill patients in 2016. This was a 
prospective, multicenter, open label randomized control trial of 1575 patients from 15 
different hospitals in the Netherlands19. Patients included those admitted to the ICU with 
presumed or proven infection and status of sepsis.  When treating those in the PCT 
guided group physicians were advised to discontinue antibiotic therapy when the 
procalcitonin concentration had decreased by 80% or more of the peak value or had 
dropped to 0.5 ng/mL or lower with the freedom to overrule if clinically necessary.  The 
primary outcome was consumption of antibiotics (defined doses per day) and duration of 
antibiotic treatment (number of 24hour periods between start and end of treatment) and 
28-day and 1-year mortality. They found that the median consumption of antibiotics 
among the PCT guided group was 7.5 daily doses and among the standard of care group 
was 9.3 daily defined doses (absolute difference: 2.69 daily defined doses, 95% CI 1.26-
4.12). They also noted a reduction from 7 days of antibiotics in the standard of care group 
to 5 days of antibiotics in the PCT group (p<0.0001). Additionally, they found the 28-day 
mortality for the procalcitonin group was 20%, while that for the standard of care group 
was 25% , a difference found to be significant (P=0.0122). This trend in mortality 
continued and at 1 year, the mortality for the PCT patients was 36% as opposed to 43% in 
the standard of care treated patients(between group absolute difference of 7.4%, 95% CI: 
1.3-13.8). The researchers attributed this reduction in mortality to the ability of 
physicians to make adequate diagnoses sooner and treat with appropriate antibiotics in a 
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more efficient manner. They postulated that often in clinical practice, antibiotics are 
started empirically if bacterial infection is suspected. If the resulting PCT is high it would 
confirm the physician’s suspicion of infection but if the PCT were to be low, this would 
provoke physicians to rethink initial diagnosis and further investigate the cause of the 
illness. It is important to note the potential conflict of interest as this was funded by 
Thermo Fischer Scientific, the manufacturer of the assay used to measure PCT in this 
study. The authors note non-adherence to the algorithm in over half of the patients which, 
like previous studies before it, could underestimate the true efficacy of PCT guided 
algorithms. The strength of this study is that it is the largest study to date investigating 
the efficacy and safety of PCT guided therapy in critically ill patients in the ICU. Overall, 
this study provided further support that, in patients with sepsis in the ICU, PCT can play 
a role in guiding antibiotic treatment.  
While data from randomized control trials suggests using PCT to discontinue 
antibiotics in the ICU is efficacious, data investigating its effectiveness when transferred 
to clinical practice is lacking. This discrepancy is causing many clinicians to be wary of 
trusting this new biomarker as a way to guide treatment to their critically ill patients. In 
2013 Hohn et. al published a study in which they analyzed the duration of antibiotic 
therapy in patients with severe sepsis in a surgical ICU in Germany over a 5 year period 
(2005-2009) after implementation of a PCT- guided algorithm .39 The authors conducted 
a retrospective ICU-database search and ultimately included 141 patients in the final 
analysis. They found significant reductions in days on antibiotic therapy each year 
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following implementation (1.0 day per year, p=0.02) from 14.3 +/- 1.2 days to 9.0 +/-1.7 
days. Their study concluded that PCT-algorithms can effectively reduce the length of 
antibiotic use when algorithms are integrated into clinical practice. This study is limited 
in that it only utilized a single hospital’s ICU in Germany which decreases its 
generalizability to practice elsewhere, but it does suggest that implementing algorithms 
into practice can produce desired results.  
As previously mentioned, in the United States, use of PCT has not been adopted 
well into practice. Chu et.al  published a study in 2017 investigating the practice patterns 
and outcomes associated with PCT use in patients with sepsis across the United States20. 
Given evidence from randomized control trials supporting the use of procalcitonin, they 
investigated how PCT is used in everyday practice among critically ill patients with 
sepsis, and observed whether there were any associations between PCT use and real 
patient outcomes20.  They conducted a retrospective cohort study of approximately 20% 
of patients with sepsis in nonfederal US hospitals in 2012. They did this using ICD-9-CM 
billing codes, first identifying PCT use from laboratory billing files and then identifying 
temporal relationships between PCT order and the time of first dose of antibiotics20. Their 
primary analysis was the association between PCT use and antibiotic days of therapy 
(DOT) during hospitalization.  Secondary outcomes they investigated were rates of new-
onset C.difficile infections and in-hospital mortality.  They identified 20,750 patients with 
sepsis in the ICU in 107 hospitals that utilized PCT. Of these patients with sepsis, 
3769(18%) had PCT measured during their hospitalization.  They found that PCT was 
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measured 1.6 +/- 5.2 days after antibiotics were started. Of patients who had a PCT 
measured, 1250 (32%) had a repeat PCT a mean of 3.2 +/- 4.6 days after the first PCT. 
Ultimately, they found that PCT orders were associated with longer antibiotic DOT 
(multivariable-adjusted relative risk,  1.17; 95% CI: 1.15-1.18) increased rates of C. 
difficile (multivariable-adjusted odds ratio, 1.42; 95% CI: 1.09-1.85) and no difference in 
mortality. The outcomes of DOT and incidence of C.difficile seem to contradict what 
randomized control trials have shown.  They approximate that in 2012, only 5% of 
patients in the United states with sepsis had a PCT level measured and, among those 5%, 
only 1 in 3 had serial PCT levels measured, suggesting possible use of an algorithm20.  
These practice patterns of PCT use that they observed in the study do not align with the 
PCT algorithms that have been used in randomized control trials – ones which have been 
shown to be both safe and efficacious in decreasing DOT without increasing risk of 
adverse outcomes. One of the limitations the authors describe was that they could not 
investigate whether individual hospitals followed a PCT algorithm. Additionally, as they 
reviewed data from billing codes they did not have access to PCT levels, thus, inhibiting 
them from having the ability to identify if clinical decisions were made in response to 
PCT results which could suggest use of an algorithm. Overall, their results demonstrate 
that PCT was not being used in practice in the way found to be efficacious. Furthermore, 
when PCT is misused, it can result in increased DOT and increased incidence of C. 
difficile, the opposite effect of that from appropriate use. The authors suggest that better 
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integration of the effective algorithms is necessary in order to see the results 
demonstrated in the RCTs in clinical practice.   
Overall, there is support from numerous studies showing the use of PCT-guided 
antibiotic de-escalation can decrease DOT and antibiotic side effects, many of them with 
a conservative bias that underestimates the true efficacy of using the algorithm. 
Furthermore, it has been shown that when implemented in clinical practice PCT can be 
efficacious19,39. Despite all this support, in the United States the serum PCT laboratory 
test has been poorly implemented into practice resulting in its misuse. Since Chu et. al,’s 
investigation of data in 2012,  the test has been in practice longer and there is likely more 
access to the test, and subsequently there are likely more physicians using PCT in 
practice. Due to the poor implementation however, there is a chance that practice patterns 
have not changed much since Chu’s 2012 study, further perpetuating PCT misuse and its 














We will conduct a retrospective cohort study of PCT use and outcomes of critically ill 
patients with sepsis adapting the methods of Chu et. al 2017. We plan to study PCT use 
in the intensive care units of Boston Medical Center, Massachusetts General Hospital, 
Beth Israel Hospital and Brigham and Women’s Hospital since 2013 using EPIC 
electronic medical records to obtain our data. We plan to first identify whether patients 
had PCT measured during their care or not. Then, if PCT was measured we will identify 
whether those patients care aligned with the FDA guidelines of PCT use to discontinue 
antibiotics had better outcomes. Among the groups we will be measuring days of 
antibiotic therapy, and incidence of new C. difficile infection.  
Project Population and Sampling:  
 
Using EPIC charting system for chart review, we will identify patients hospitalized in the 
Boston area ICUs. To gain access to adequate sample size we plan to access charts from 
the following Hospital’s ICUs: Boston Medical Center, Massachusetts’s General 
Hospital, Beth Israel Hospital and Brigham and Women’s Hospital. We will include 
patients who were admitted to the ICU with sepsis as a diagnosis in EPIC charting system 
on antibiotic therapy from 2013-2018. Using the electronic medical record, we will 
identify when they first received antibiotics. We will exclude patients who did not receive 
antibiotics. Sample size estimates were calculated using parameters from Chu et. al. 
Assuming an α of 0.05 and a β of 0.20, the proportion of participants that had PCT 
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measured of  0.18 ,20  a risk of CDI in the baseline group  of  0.04,40 and an OR for 
developing new CDI in patients who had PCT measured compared to not of  1.42,20  we 
will need to identify at least 9,657 patients that meet ( n=7,919 control, n=1,738 PCT 
ordered). The sample size needed to detect our primary outcome of mean antibiotic 
duration is much less (n=605 calculated using α=0.5,β=0.2, proportion of participants that 
had PCT measured=0.18,  E=2.7 days on antibiotic therapy, SD=9.1days on antibiotic 
therapy17,20). Thus, in order to have sufficient power for this study to detect either 
outcome, we will use the sample size needed to detect a change in incidence of new CDI 
amongst patients with sepsis.  
Exposure Groups: 
 
Figure 1: the diagram above illustrates how patients will be stratified into exposure 
groups for analysis. 
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In reviewing the patient charts, we will identify which patients had PCT levels drawn, 
record the levels and, if the PCT levels meet criteria as outlined by the FDA for 
discontinuation, whether or not antibiotics were stopped within 24 hours. The exposure 
groups are outlined above in Figure 1. The control group will be patients with sepsis who 
did not have a PCT drawn during their stay in the ICU. One exposure group, Group 1, 
will be those who had PCT ordered with antibiotic cessation that aligns with the FDA 
guidelines outlined in Figure 2. These will be patients who either had a PCT level that 
was <0.5 ng/mL or a drop of 80% from the peak PCT to the current PCT, and then had 
observed discontinuation of antibiotics within 8 hours of the result. Given that the assay 
takes 2-4 hours to result39, if drawn at the beginning of a shift and typical ICU shift of 10-
12 hours this would give 8 hours to see the result by the end of their shift and respond. 
However, in the event that the test was ordered midday or at the end of day, we will allow 
24 hours for providers to respond to PCT levels.  
 
Figure 2: FDA recommended protocol for discontinuing antibiotics based on 
procalcitonin concentration11 
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The second exposure group, Group 2, will be those who had PCT ordered during their 
stay but whose antibiotic course was not discontinued according to the PCT algorithms 
outlined by the FDA.  
Project Variables and Measurement Tools:  
The control group ( Figure 1) will be those who have sepsis in the ICU, on antibiotics 
who did not have PCT measured during their stay. The independent variable will be use 
of PCT (Figure 1) – either Group 1 whose PCT use aligns with FDA algorithm  or 
Group 2 whose serum PCT was measured but the use does not align with the algorithm. 
The dependent variables will include; the primary outcome of duration of antibiotic 
therapy throughout hospitalization including both throughout ICU stay and after, the 
secondary outcome of incidence of new CDI as a surrogate for antibiotic overuse,  as well 
as patient demographics, patient comorbidities, attending physician specialties and sites 
of infection (Table 1). Duration of antibiotic therapy will be calculated as 24h periods on 
antibiotic therapy. Incidence of CDI will be limited to new-onset infections during period 
of ICU stay. In hospital mortality will be defined as mortality from any cause while 
hospitalized and will include patients discharged to hospice or whose goals of care 
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Table 1: Patient Characteristics Associated With Use of Procalcitionin 
Age year 
Sex M, F 
Race white, black, other 
Attending specialty internal medicine, Surgical, 
Pulmonary/Critical care 
Infection Site  pneumonia, gastrointestinal, urinary tract 
infection, skin/soft tissue, bacteremia 
Patient Comorbidities Heart Failure, Diabetes, Hypertension, 
Coronary artery disease/Myocardial 
Infarction, Chronic Kidney disease, 
Chronic obstructive pulmonary disease, 
peripheral vascular disease, cancer, 
cirrhosis, dementia 
 
Recruitment & Data Collection:  
Request will be sent to Partner’s Health Care to obtain access to EPIC electronic medical 
records of patients within their hospitals. All patient charts identified meeting criteria 
within the ICUs of BMC, MGH, BIH, and BWH over the period of 2013-2018 will have 
electronic medical records obtained, maintaining patient anonymity. Charts will be 
reviewed for use of PCT and resulting level, antibiotic therapy and incidence of new C. 
difficile infection during their hospital stay.  The data will be collected via review of 
patient’s electronic medical record by two trained data abstractors. We will have data 
abstractors trained following standardized data abstraction procedures and the 
information will be recorded in a Microsoft Exel spreadsheet template. To ensure data 
collection is standardized, the collection process will be overseen and reviewed by study 
coordinator.  
 




The following analysis methodology is adapted from Chu. et. al. 2017. We will report 
duration of antibiotic therapy using means and standard deviations. We will report the 
following variables as percentages: use of PCT (Group 1&2), use of PCT 
algorithm(Group 1),  PCT use without algorithm(Group2) and  incidence of CDI. To 
assess our primary aim, we will first compare mean durations of antibiotic therapy 
between the control group and those who had a procalcitonin level checked (Group 1 and 
Group 2) using an unpaired t-test. We will then compare mean durations of antibiotic 
therapy among Control, Group 1 and Group 2 using a one-way ANOVA test. Should a 
statistically significant difference result, we will conduct pairwise comparisons between 
Control vs Group 1, Control vs Group 2 and Group 1 vs Group 2, using Bonferroni 
calculations to adjust the alpha error to account for multiple comparions. To evaluate our 
secondary aim we will first compare, using a chi-square test, the difference in CDI 
incidence between Control and those that used PCT (combined Group1 and Group2). 
Next we will compare using a chi-square test among Control, Group 1 and Group 2. If 
there is any significant difference we will then run pairwise analysis with subsequent chi-
square tests using Bonferroni corrections to decrease chance of committing an alpha 
error. Finally, with the assistance of a biostatistician we will calculate multivariable 
adjusted odds ratios to determine if there are any association between patient 
characteristics our exposure groups; control, PCT use (Group 1 and Group 2), Group 1 
and Group 2.  
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Timeline and Resources:  
Training data abstractors, data collection will take 2 years for allowing data abstractors to 
find data on about one subject every day. Data analysis will take 6-8 months. The study 
should be completed in 3 years. Key personnel for this study will include a primary 
investigator, co-investigators, a biostatistician, a study coordinator and 20 data 
abstractors. We will require office space for 15 people.  We will use Microsoft Excel for 
basic statistical analysis 
Institutional review board: 
We intend to submit research plan to Boston University Medical Campus Institutional 
Review board for review and approval of our study procedure as exempt human subjects 
research. Our planned study will constitute research with human subjects but will also 
meet requirements of low-risk human subject research as follows. Our study will fall 
under the category of research that involves collection and study of existing data, records 










This study has several limitations that could affect the outcome. First, the study is limited 
because we will be collecting data that occurred within an 8-hr window as defined by our 
methods. This is a subjectively defined time period and therefore, there is a chance we 
would miss orders that occurred outside of this 8-hour time window that could have been 
placed in response to the PCT value. Second, it is possible that we will not identify 
enough people whose objective history of care aligns with the algorithm. In this scenario 
we would not be able to make a conclusion about the efficacy of the proposed algorithm 
in clinical practice. Next, as with much observational research, we cannot account for and 
measure all possible confounding variables that may affect outcome as we are only 
accounting for a defined list of possible cofounders. This study will be limited in its 
generalizability as well. The hospitals involved are all teaching hospitals in Boston, 
Massachusetts. The availability and use of PCT in hospitals likely varies from state to 
state and even from urban to rural centers within Massachusetts. One strength of this 
study, compared to Chu et. al. where PCT lab values were not accessible, is that we will 
be able to access the PCT measurements and analyze whether antibiotic orders were 
possibly changed as a result. Because we will not know exactly whether providers were 
using an algorithm to guide their management decisions, this data will not be a measure 
of adherence but rather will be objective measurements that will show results of 
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antibiotic decisions either are or are not in accordance with the current proposed 
algorithm. 
Summary:  
Antibiotic overuse in our country and across the world is a problem that is accelerating 
the development of resistance.1–3 With 50% of antibiotics prescribed deemed unnecessary 
by the CDC 1, parts of antibiotic stewardship campaigns across the country are aimed at 
curtailing use of inappropriate antibiotic use. One facet of these extensive antibiotic 
stewardship campaigns includes using PCT to discontinue antibiotics sooner.5 
Procalcitonin, a serum peptide that is secreted in response to bacterial toxins,6,7 has been 
shown to be more specific to bacterial infections than general markers of inflammation 
like CRP.4,9,31,33 Due to high prevalence and mortality of sepsis, clinicians have been 
focused on determining better methods of detection and management23,26,30 and PCT 
plays a role in this as well. Given the risks of adverse effects14–16 with extended antibiotic 
use PCT has been approved to be used to guide discontinuation of antibiotic therapy to 
ultimately decrease antibiotic exposure in the critically ill.  
             Numerous randomized control trials have found significant decreases by 2-3 days 
when a PCT algorithm is used to guide de-escalation4,12,17–20,36–38 despite adherence to 
protocols of around 50%. While this type of adherence underestimates the true efficacy it 
likely displays expected results if algorithms were used in clinical practice. Furthermore, 
it has been shown that using PCT to guide antibiotic therapy is safe for the patients and 
does not increase mortality19,37. Evidence of patterns of  PCT use in the United States in 
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2012 showed that PCT was not consistently being used in patients with sepsis which 
resulted in longer duration of antibiotic therapy and increased rates of C. difficile 
infection20. Since then, more hospitals have acquired access to PCT, more clinicians are 
familiar with it and the FDA has approved an algorithm for discontinuing antibiotics in 
patients with sepsis in the ICU. This study plans to identify whether practice patterns 
have evolved since 2012 and provide evidence that using the PCT algorithm in patients 
with sepsis in the ICU to guide discontinuation of antibiotics can decrease duration of 
therapy and incidence of CDI. If a tool that has been shown to be effective RCTs, and 
misuse in clinical practice is resulting in negative consequences, then further 
investigation needs to be performed to better implement the PCT algorithm in a way that 
encourages adherence.  
 Public health significance 
Due to the increased availability of PCT over the past few years, this study may find that 
there is increased misuse of PCT since 2012. By assessing the efficacy of the algorithm, 
the outlined study has the potential to show that use of FDA’s de-escalation algorithm in 
practice will decrease DOT and CDI in patients whose physicians follow it. If these 
findings are observed, it will call for further action to better implement the algorithm into 
practice in to achieve the desired effect. It would also add validity to the effectiveness of 
this measure and hopefully more clinicians would feel more of an obligation to adhere to 
the algorithm as a way to practice good antibiotic stewardship. Ultimately, demonstrating 
the efficacy of the algorithm has the ability to influence antibiotic practice on a large 
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scale. This test that is easy to use, quick to result can become a mainstream guide to 
antibiotic management, thus giving us one more way to limit antibiotic use and decelerate 
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